JPMorgan downgraded Merrimack Pharma (NASDAQ:MACK) from Overweight to Neutral in a report released today.
- Updated: October 7, 2016
Yesterday Merrimack Pharma (NASDAQ:MACK) traded -1.42% lower at $5.98. The company’s 50-day moving average is $5.19 and its 200-day moving average is $6.22. The last closing price is down -5.18% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time period. 541,655 shares of the stock traded hands, down from an average trading volume of 2,555,460
JPMorgan has downgraded Merrimack Pharma (NASDAQ:MACK) from Overweight to Neutral in a report released on 10/07/2016.
With a total market value of $0, Merrimack Pharma has with a one year low of $4.39 and a one year high of $10.85 .
Brief Synopsis About Merrimack Pharma (NASDAQ:MACK)
Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing medicines consisting of therapeutics paired with companion diagnostics for the treatment of cancer. Its therapeutic oncology candidates in clinical development include MM-398, MM-302, MM-121, MM-141 and MM-151. Its ONIVYDE (irinotecan liposome injection), also known as MM-398, is an encapsulation of the marketed chemotherapy drug irinotecan in a liposomal formulation. MM-302 is an antibody drug conjugated liposomal doxorubicin that targets the ErbB2 (HER2) receptor. MM-121 is a fully human monoclonal antibody that targets Erb-B2 Receptor Tyrosine Kinase 3 (ErbB3). MM-141 is a fully human tetravalent bispecific antibody designed to block tumor survival signals by targeting receptor complexes. MM-151 is an oligoclonal therapeutic designed to bind to non-overlapping epitopes of EGFR (ErbB1).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.